UBS Group
FBLG icon

UBS Group’s FibroBiologics FBLG Stock Holding History

UBS Group’s Portfolio FBLG Stock Details FBLG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.55K Sell
5,721
-318
-5% -$1.89K ﹤0.01% 8567
2025
Q4 		$27.2K Buy
6,039
+2,167
+56% +$15.3K ﹤0.01% 7587
2025
Q3 		$42.3K Sell
3,872
-1,642
-30% -$19.7K ﹤0.01% 7685
2025
Q2 		$68.6K Sell
5,514
-129
-2% -$2.33K ﹤0.01% 7524
2025
Q1 		$102K Sell
5,643
-767
-12% -$21.9K ﹤0.01% 7037
2024
Q4 		$256K Buy
6,410
+4,242
+196% +$228K ﹤0.01% 6305
2024
Q3 		$134K Sell
2,168
-1,735
-44% -$115K ﹤0.01% 6155
2024
Q2 		$389K Buy
3,903
+3,902
+390,200% +$744K ﹤0.01% 5192
2024
Q1 		$303 Buy
+1
New +$240 ﹤0.01% 8638

Other funds holding FBLG

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FEG
Fund Evaluation Group Cincinnati, Ohio $3.25B AUM 14.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CFP
Cascade Financial Partners San Diego, California $970M AUM 19.9% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return
VGA
Vanguard Global Advisers Malvern, Pennsylvania $187B AUM
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS Group's FBLG Position: Q1 2026 in Review

UBS Group reduced its FibroBiologics (FBLG) stake by 5.3% in Q1 2026, selling an estimated $1.89K and leaving 5,721 shares worth $7.55K. The position accounts for ﹤0.01% of the portfolio, ranked #8567.

UBS Group first reported a position in FBLG in Q1 2024 and has held it in 9 quarters since. The position peaked at $389K in Q2 2024. 17 funds tracked by Wall St. Rank hold FBLG as of Q1 2026.

  • UBS Group held 5,721 shares of FibroBiologics worth $7.55K as of Q1 2026.
  • UBS Group sold 318 FibroBiologics shares in Q1 2026, an estimated $1.89K.
  • FibroBiologics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #8567 holding.
  • UBS Group first reported a position in FibroBiologics in Q1 2024 and has held it in 9 quarters since.
  • UBS Group's FibroBiologics position peaked at $389K in Q2 2024.
  • 17 funds tracked by Wall St. Rank held FibroBiologics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.